Towa Pharmaceutical Co., Ltd. (TYO:4553)
3,100.00
-25.00 (-0.80%)
Jun 9, 2025, 3:30 PM JST
Towa Pharmaceutical Balance Sheet
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Cash & Equivalents | 45,471 | 29,650 | 24,257 | 32,830 | 22,915 | Upgrade
|
Cash & Short-Term Investments | 45,471 | 29,650 | 24,257 | 32,830 | 22,915 | Upgrade
|
Cash Growth | 53.36% | 22.23% | -26.11% | 43.27% | 22.45% | Upgrade
|
Receivables | 71,631 | 71,657 | 54,392 | 50,748 | 45,784 | Upgrade
|
Inventory | 108,287 | 101,072 | 92,927 | 72,701 | 60,951 | Upgrade
|
Other Current Assets | 21,917 | 15,339 | 11,414 | 10,585 | 7,640 | Upgrade
|
Total Current Assets | 247,306 | 217,718 | 182,990 | 166,864 | 137,290 | Upgrade
|
Property, Plant & Equipment | 168,423 | 153,642 | 127,004 | 100,857 | 85,898 | Upgrade
|
Long-Term Investments | 3,213 | 3,006 | 3,104 | 3,035 | 3,277 | Upgrade
|
Goodwill | 28,115 | 32,568 | 34,613 | 44,647 | 7,050 | Upgrade
|
Other Intangible Assets | 17,727 | 18,018 | 18,332 | 9,455 | 7,913 | Upgrade
|
Long-Term Deferred Tax Assets | 6,037 | 5,699 | 5,303 | 5,075 | 4,239 | Upgrade
|
Other Long-Term Assets | 2 | 2 | 1 | 2 | 1 | Upgrade
|
Total Assets | 470,823 | 430,653 | 371,347 | 329,935 | 245,668 | Upgrade
|
Accounts Payable | 30,041 | 26,372 | 36,070 | 29,076 | 23,168 | Upgrade
|
Accrued Expenses | 112 | 96 | 117 | 108 | 100 | Upgrade
|
Short-Term Debt | 10,057 | 6,927 | 15,224 | 52,762 | 3,486 | Upgrade
|
Current Portion of Long-Term Debt | 18,023 | 10,120 | 7,527 | 12,172 | 7,181 | Upgrade
|
Current Portion of Leases | 1,383 | - | - | - | - | Upgrade
|
Current Income Taxes Payable | 20,334 | 23,911 | 14,012 | 15,536 | 12,069 | Upgrade
|
Other Current Liabilities | 7,989 | 12,692 | 5,579 | 5,419 | 5,512 | Upgrade
|
Total Current Liabilities | 87,939 | 80,118 | 78,529 | 115,073 | 51,516 | Upgrade
|
Long-Term Debt | 195,077 | 189,124 | 150,314 | 79,194 | 74,098 | Upgrade
|
Long-Term Leases | 11,801 | - | - | - | - | Upgrade
|
Other Long-Term Liabilities | 4,241 | 5,299 | 5,288 | 2,952 | 2,916 | Upgrade
|
Total Liabilities | 299,199 | 274,761 | 234,453 | 197,766 | 129,070 | Upgrade
|
Common Stock | 4,717 | 4,717 | 4,717 | 4,717 | 4,717 | Upgrade
|
Additional Paid-In Capital | 7,841 | 7,838 | 7,837 | 7,837 | 7,834 | Upgrade
|
Retained Earnings | 150,502 | 134,452 | 121,232 | 122,131 | 108,629 | Upgrade
|
Treasury Stock | -5,586 | -5,606 | -5,608 | -5,608 | -5,626 | Upgrade
|
Comprehensive Income & Other | 14,150 | 14,491 | 8,716 | 3,092 | 1,044 | Upgrade
|
Shareholders' Equity | 171,624 | 155,892 | 136,894 | 132,169 | 116,598 | Upgrade
|
Total Liabilities & Equity | 470,823 | 430,653 | 371,347 | 329,935 | 245,668 | Upgrade
|
Total Debt | 236,341 | 206,171 | 173,065 | 144,128 | 84,765 | Upgrade
|
Net Cash (Debt) | -190,870 | -176,521 | -148,808 | -111,298 | -61,850 | Upgrade
|
Net Cash Per Share | -3877.50 | -3586.33 | -3023.21 | -2211.60 | -1206.18 | Upgrade
|
Filing Date Shares Outstanding | 49.23 | 49.22 | 49.22 | 49.22 | 49.21 | Upgrade
|
Total Common Shares Outstanding | 49.23 | 49.22 | 49.22 | 49.22 | 49.21 | Upgrade
|
Working Capital | 159,367 | 137,600 | 104,461 | 51,791 | 85,774 | Upgrade
|
Book Value Per Share | 3486.37 | 3167.24 | 2781.16 | 2685.17 | 2369.18 | Upgrade
|
Tangible Book Value | 125,782 | 105,306 | 83,949 | 78,067 | 101,635 | Upgrade
|
Tangible Book Value Per Share | 2555.14 | 2139.49 | 1705.52 | 1586.02 | 2065.14 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.